108 related articles for article (PubMed ID: 11350019)
1. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease.
Sarno M; Sarno L; Baylink D; Drinkwater B; Farley S; Kleerekoper M; Lang R; Lappe J; Licata A; McClung M; Miller P; Nattrass S; Recker R; Schwartz EN; Tucci JR; Wolf S; Powell H; Tjersland G; Warnick GR
Clin Chem Lab Med; 2001 Mar; 39(3):223-8. PubMed ID: 11350019
[TBL] [Abstract][Full Text] [Related]
2. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links.
Sarno M; Powell H; Tjersland G; Schoendorfer D; Harris H; Adams K; Ogata P; Warnick GR
Clin Chem; 1999 Sep; 45(9):1501-9. PubMed ID: 10471653
[TBL] [Abstract][Full Text] [Related]
3. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
[TBL] [Abstract][Full Text] [Related]
4. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
5. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
6. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
Adolf D; Wex T; Jahn O; Riebau C; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S; Piatek S
Maturitas; 2012 Feb; 71(2):169-72. PubMed ID: 22197348
[TBL] [Abstract][Full Text] [Related]
7. Urinary bone resorption markers in patients with metabolic bone disorders.
Ohishi T; Kushida K; Takahashi M; Kawana K; Yagi K; Kawakami K; Horiuchi K; Inoue T
Bone; 1994; 15(1):15-20. PubMed ID: 8024845
[TBL] [Abstract][Full Text] [Related]
8. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
[TBL] [Abstract][Full Text] [Related]
9. Discrimination ability of pyridinoline crosslinks related markers for bone resorption in postmenopause and osteoporosis.
Takahashi M; Kushida K; Kawana K; Hoshino H; Inoue T
Endocr Res; 1997; 23(1-2):105-17. PubMed ID: 9187542
[TBL] [Abstract][Full Text] [Related]
10. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
11. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
12. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
13. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
14. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
15. Biochemical markers of bone turnover.
Delmas PD
J Bone Miner Res; 1993 Dec; 8 Suppl 2():S549-55. PubMed ID: 8122526
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
17. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
18. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME
Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis.
Yilmaz N; Bayram M; Erbåğci AB; Kilinçer MS
Clin Chem Lab Med; 1999 Feb; 37(2):137-43. PubMed ID: 10219502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
